Schweizer Firma erhält Felix Burda Award für Bluttest, der Darmkrebs erkennt Ein Biotech-Unternehmen hat einen Bluttest entwickelt, der Darmkrebs und dessen Vorstufen mit hoher Wahrscheinlichkeit erkennt. Die Basis dafür bilden Biomarker im Blut. Für diesen Fortschritt in der Darmkrebs-Vorsorge erhalten sie den Felix Burda Award 2021. Im zweiten Teil der virtuellen Preisverleihung geht der
Novigenix Wins the 2021 Felix Burda Award in Medicine & Science • Category ‘Innovation in Immuno-Transcriptomics for Early Detection of Colorectal Cancer’ • Award recognizes excellence in innovation and impact in early detection of cancer LAUSANNE, SWITZERLAND - July 22, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision
Newly discovered blood signature presented at ESMO 2020 LAUSANNE, SWITZERLAND – 07:00 CET, September 17th, 2020 – Novigenix SA, a pioneer in Immuno-Transcriptomics for precision oncology, today announced a new Immuno-Transcriptomic signature for predicting response to immunotherapy in metastatic urothelial cancer patients. The data are presented at the European Society for Medical Oncology (ESMO)
Test to measure response to radiopharmaceutical therapy LAUSANNE, SWITZERLAND - 07:00 CET, October 14, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.
LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational
ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief